The Role of CD19 Cartel Cells in the Treatment of Cytokine Release Syndrome

Neralisha is in the pediatric oncology branch at the intramural program of the National Cancer Institute. She wanted to address that aspect of progressive inflammatory response despite first-line therapies as an on-med need with cytokine release syndrome and ICANN's. Neralisha: I think one of the biggest things is really in terms of thinking about some of these alternative pharmacotherapies that potentially can be used to target direct cytokines.